Abstract
Lowering blood pressure (BP) using antihypertensive medicines lowers the risk of target organ failure as well as the occurrence of cardiovascular disease. The most common modifiable risk factor for death and disability is hypertension, which is associated with strokes, increased coronary and systemic atherosclerosis, heart problems, and chronic kidney diseases (CKD). The majority of deaths and disabilities globally now result from cardiovascular diseases (CVDs), mainly in low- and middle-income nations. Numerous genetic, behavioral, and environmental risk factors all contribute to hypertension, a significant component in the advancement of CVD. Given the significance of protein-ligand interactions in structure-based therapy development, we molecularly docked nifedipine to the cardiovascular target protein to determine the drug’s binding affinity. The Angiotensin Converting Enzyme (Target hypertension Protein) three-dimensional (3D) structure was docked using the Autodock tool, which was retrieved from the Protein Data Bank (PDB). Our analysis indicates that nifedipine is an effective choice for treating hypertension and reducing the symptoms of angina (chest pain).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
